Image courtesy of Sorin Group
January 5, 2015 — Sorin Group announced U.S. Food and Drug Administration (FDA) clearance for Memo 3-D ReChord, a semi-rigid annuloplasty ring for mitral valve repair.
The device incorporates a chordal guide system into the existing Memo 3-D ring to simplify and standardize the approach to artificial chord replacement. Memo 3-D ReChord’s unique design streamlines mitral repair procedures while allowing surgeons to obtain reproducible results even in advanced chordal reconstructions.
Features include:
- A unique temporary chordal guide system that simplifies artificial chord replacement
- Sorin's Carbofilm coating to enhance hemo-compatibility
- Cell-structure design to accommodate the mitral saddle shape while enabling the physiological 3-D motion of the native annulus.
Steven F. Bolling, M.D., professor of cardiac surgery, University of Michigan Health System, who conducted the first implantation of the ring in the United States, commented on his experience: “The Memo 3D ReChord is simple to use with a minimal learning curve for new users. The chordal guide system gives surgeons more confidence when performing anterior mitral leaflet repairs with Gore-Tex chordae.
I believe that using the Memo 3D ReChord allows surgeons to deliver more reproducible results during this procedure, ultimately improving patient outcomes. Offering a solution that standardizes artificial chord replacement may actually increase the number of anterior mitral leaflet repairs performed each year.”
For more information: www.sorin.com
